Heplisav

From WikiCover

Jump to: navigation, search

Dynavax's hepatitis B virus (HBV) vaccine, Heplisav, is based on its proprietary immunostimulatory sequence (ISS) that specifically targets Toll-Like Receptor 9 (TLR9) to stimulate an innate immune response. Heplisav combines ISS with HBV surface antigen (HBsAg) and is designed to significantly enhance the level, speed and longevity of protection. Previously reported clinical trials results have shown 100% seroprotection after two doses in subjects 18 to 39 years of age, and after three doses in difficult-to-immunize subjects 40 to 70 years of age.

Retrieved from "http://www.wikicover.com/Heplisav"